QQQ   431.63 (+0.13%)
AAPL   173.19 (+0.29%)
MSFT   414.60 (+0.23%)
META   501.59 (+0.27%)
GOOGL   155.02 (+0.10%)
AMZN   183.40 (-0.12%)
TSLA   154.50 (-4.32%)
NVDA   869.08 (+1.05%)
AMD   163.17 (+1.78%)
NIO   3.76 (-3.34%)
BABA   69.54 (-1.53%)
T   16.08 (-0.99%)
F   12.06 (-1.39%)
MU   119.20 (-1.79%)
GE   154.87 (+0.76%)
CGC   6.69 (-4.15%)
DIS   113.21 (+0.23%)
AMC   2.48 (+0.40%)
PFE   25.92 (+0.04%)
PYPL   63.40 (-0.17%)
XOM   119.29 (-0.33%)
QQQ   431.63 (+0.13%)
AAPL   173.19 (+0.29%)
MSFT   414.60 (+0.23%)
META   501.59 (+0.27%)
GOOGL   155.02 (+0.10%)
AMZN   183.40 (-0.12%)
TSLA   154.50 (-4.32%)
NVDA   869.08 (+1.05%)
AMD   163.17 (+1.78%)
NIO   3.76 (-3.34%)
BABA   69.54 (-1.53%)
T   16.08 (-0.99%)
F   12.06 (-1.39%)
MU   119.20 (-1.79%)
GE   154.87 (+0.76%)
CGC   6.69 (-4.15%)
DIS   113.21 (+0.23%)
AMC   2.48 (+0.40%)
PFE   25.92 (+0.04%)
PYPL   63.40 (-0.17%)
XOM   119.29 (-0.33%)
QQQ   431.63 (+0.13%)
AAPL   173.19 (+0.29%)
MSFT   414.60 (+0.23%)
META   501.59 (+0.27%)
GOOGL   155.02 (+0.10%)
AMZN   183.40 (-0.12%)
TSLA   154.50 (-4.32%)
NVDA   869.08 (+1.05%)
AMD   163.17 (+1.78%)
NIO   3.76 (-3.34%)
BABA   69.54 (-1.53%)
T   16.08 (-0.99%)
F   12.06 (-1.39%)
MU   119.20 (-1.79%)
GE   154.87 (+0.76%)
CGC   6.69 (-4.15%)
DIS   113.21 (+0.23%)
AMC   2.48 (+0.40%)
PFE   25.92 (+0.04%)
PYPL   63.40 (-0.17%)
XOM   119.29 (-0.33%)
QQQ   431.63 (+0.13%)
AAPL   173.19 (+0.29%)
MSFT   414.60 (+0.23%)
META   501.59 (+0.27%)
GOOGL   155.02 (+0.10%)
AMZN   183.40 (-0.12%)
TSLA   154.50 (-4.32%)
NVDA   869.08 (+1.05%)
AMD   163.17 (+1.78%)
NIO   3.76 (-3.34%)
BABA   69.54 (-1.53%)
T   16.08 (-0.99%)
F   12.06 (-1.39%)
MU   119.20 (-1.79%)
GE   154.87 (+0.76%)
CGC   6.69 (-4.15%)
DIS   113.21 (+0.23%)
AMC   2.48 (+0.40%)
PFE   25.92 (+0.04%)
PYPL   63.40 (-0.17%)
XOM   119.29 (-0.33%)

Quest Diagnostics (DGX) Stock Forecast & Price Target

$128.46
-0.18 (-0.14%)
(As of 09:55 AM ET)

Quest Diagnostics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$144.18
12.24% Upside
High Forecast$160.00
Average Forecast$144.18
Low Forecast$130.00
TypeCurrent Forecast
4/17/23 to 4/16/24
1 Month Ago
3/18/23 to 3/17/24
3 Months Ago
1/17/23 to 1/17/24
1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$144.18$145.92$146.00$152.45
Predicted Upside12.24% Upside10.00% Upside7.02% Upside7.59% Upside
Get Quest Diagnostics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

DGX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Quest Diagnostics Stock vs. The Competition

TypeQuest DiagnosticsMedical CompaniesS&P 500
Consensus Rating Score
2.18
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside12.24% Upside882.15% Upside11.23% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/20/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Hold$145.00+12.88%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$135.00+6.23%
2/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$140.00 ➝ $155.00+22.76%
1/3/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$145.00+2.97%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$140.00 ➝ $160.00+16.82%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$130.00 ➝ $145.00+6.69%
12/7/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$135.00 ➝ $137.00+1.42%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$148.00 ➝ $149.00+10.34%
11/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$130.00 ➝ $140.00+4.09%
10/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$136.00 ➝ $130.00+5.03%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$145.00+6.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:17 AM ET.

DGX Price Target - Frequently Asked Questions

What is Quest Diagnostics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Quest Diagnostics stock is Hold based on the current 9 hold ratings and 2 buy ratings for DGX. The average twelve-month price prediction for Quest Diagnostics is $144.18 with a high price target of $160.00 and a low price target of $130.00. Learn more on DGX's analyst rating history.

Do Wall Street analysts like Quest Diagnostics more than its competitors?

Analysts like Quest Diagnostics less than other Medical companies. The consensus rating for Quest Diagnostics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how DGX compares to other companies.

Is Quest Diagnostics being upgraded by Wall Street analysts?

Over the previous 90 days, Quest Diagnostics's stock had 1 upgrade by analysts.

Does Quest Diagnostics's stock price have much upside?

According to analysts, Quest Diagnostics's stock has a predicted upside of 8.27% based on their 12-month stock forecasts.

What analysts cover Quest Diagnostics?

Quest Diagnostics has been rated by Jefferies Financial Group, Leerink Partnrs, SVB Leerink, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:DGX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners